Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS OPENS NEW OFFICE IN HAMILTON TO EXPAND ITS ACCUM RADIOPHARMACEUTICAL PLATFORM

Defence Therapeutics Inc. has opened a new office at McMaster Innovation Park in Hamilton, Ont., supporting the company's expanding radiopharmaceutical research and business development activities.

Hamilton has emerged as one of Canada's leading hubs for radiopharmaceutical innovation, bringing together world-class capabilities spanning isotope production, radiopharmaceutical discovery, translational research, GMP (good manufacturing practice) manufacturing and clinical translation. Anchored by McMaster University, alongside internationally recognized institutions and a rapidly expanding ecosystem of radiopharmaceutical companies, the region is positioning Hamilton at the forefront of next-generation precision medicine while helping establish Canada as a global leader in the field.

"Our expansion into McMaster Innovation Park reflects both the growth of our company and the increasing momentum of our radiopharmaceutical programs," said Sebastien Plouffe, chief executive officer of Defence Therapeutics. "As we continue to advance the Accum platform, this strategic positioning allows us to build new collaborations, access exceptional expertise and further strengthen the foundation we are building to develop the next generation of precision oncology therapies."

McMaster Innovation Park has become home to a growing community of life sciences innovators, offering specialized infrastructure and a collaborative environment designed to accelerate scientific innovation and commercialization. "We are pleased to welcome Defence Therapeutics to McMaster Innovation Park. Companies like Defence strengthen the collaborative innovation ecosystem that helps scale companies and advance emerging strengths in areas like radiopharmaceuticals and precision oncology. We look forward to supporting their continued growth and success," said Dr. Gailene Tobin Vandenheuvel, chief executive officer of McMaster Innovation Park.

The new Hamilton location complements Defence's expanding research capabilities and reflects the company's broader strategy of building the scientific infrastructure, expertise and partnerships needed to maximize the potential of its Accum platform across multiple precision oncology applications, including antibody-drug conjugates (ADCs), radiopharmaceuticals and other complex biologics.

About Defence Therapeutics Inc.

Defence Therapeutics is a publicly traded biotechnology company committed to making cancer treatment more effective and safer. Using its Accum precision drug delivery platform, Defence is working to enhance the potency of ADCs and other complex biologics at lower doses, with the goal of reducing side effects and improving access to advanced therapies. By pursuing cutting-edge science and collaborating with pharma and biotech partners, Defence strives to bring transformative therapies to patients who need them most.

We seek Safe Harbor.